Regeneron Pharmaceuticals (REGN)

$753.55 -1.96 (-0.26%)
Market Cap 79.20B
Revenue (ttm) 14.20B
Net Income (ttm) 4.41B
EPS (ttm) N/A
PE Ratio 20.60
Forward PE 21.69
Profit Margin 31.07%
Debt to Equity Ratio 0.06
Volume 721,100
Avg Vol 987,808
Day's Range N/A - N/A
Shares Out 105.10M
Stochastic %K 38%
Beta 0.39
Analysts Strong Sell
Price Target $829.19

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
Information_Master
Information_Master Jan. 24 at 3:31 PM
PORTFOLIO UPDATE Natan YTD: +4.0% S&P500 YTD: +1.0% TOTAL RETURNS (Jan 2022) Natan's portfolio: +132.1% *Benchmark: +44.2% S&P500: +53.5% MY POSITIONS: 17.3% | Transmedics $TMDX 14.6% | Pinduoduo $PDD 9.4% | Alibaba $BABA 8.0% | Robinhood $HOOD 8.0% | Regeneron $REGN ...... 👉Click to view @Information_Master for timely updates amid the volatility..
0 · Reply
gargoyl
gargoyl Jan. 23 at 2:56 PM
$BLRX 🦍 👀 set up for beast mode … watch .. $VSTM $REGN $XBI
0 · Reply
gargoyl
gargoyl Jan. 23 at 6:41 AM
$BLRX the new trend is economic fundamentals after value as the bull trend broadens into full market, well, add growth to that and you have a perfect trifecta storm on a currently little 🧢 cap. Instinct says the appearance of manipulated weakness is a ruse for accumulation, but only until the second a milestone hits , most likely equivalent to current market cap, the veil be removed and MM can’t shade the demand in the dark pool and a tenuous spread book of wide Bid and Ask. Is today the day , it’s inevitable. Long the 🦋 🎯 $18 $XBI $REGN
0 · Reply
Iwannagofast1
Iwannagofast1 Jan. 22 at 3:08 PM
$REGN My 4 401K longs TSM INTC SNDK AMD . Do your thing. 13 shorts and have mass puts in liquid accts. Software getting killed still so that’s good news
0 · Reply
50bps
50bps Jan. 22 at 3:05 PM
$REGN 👀
0 · Reply
GT1313
GT1313 Jan. 22 at 2:58 PM
$REGN I need a 5% day
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 22 at 2:53 PM
$REGN they need to give a PR-update on the pending CRL?
0 · Reply
Dy2ski
Dy2ski Jan. 21 at 12:08 PM
$OCUL $MRK Interesting. Solid addition with the $REGN Eylea link beyond the possible acquisition link.
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 21 at 2:31 AM
$REGN Share Price: $733.95 Contract Selected: Feb 13, 2026 $740 Calls Buy Zone: $23.29 – $28.77 Target Zone: $43.52 – $53.20 Potential Upside: 76% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
tasha655
tasha655 Jan. 20 at 6:08 PM
$BMEA $REGN
0 · Reply
Latest News on REGN
Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

Jan 23, 2026, 3:25 PM EST - 1 day ago

Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Jan 21, 2026, 12:05 PM EST - 3 days ago

Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:16 PM EST - 12 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

Jan 12, 2026, 1:30 PM EST - 12 days ago

Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba

BABA COF UNH

Regeneron Just Moved From Underperform To Buy - Here's Why

Jan 7, 2026, 4:18 PM EST - 17 days ago

Regeneron Just Moved From Underperform To Buy - Here's Why

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Dec 23, 2025, 1:00 AM EST - 4 weeks ago

Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

SNY

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Dec 23, 2025, 1:00 AM EST - 4 weeks ago

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 4:05 PM EST - 4 weeks ago

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Regeneron: The Turnaround Is Gaining Steam

Dec 20, 2025, 9:30 AM EST - 5 weeks ago

Regeneron: The Turnaround Is Gaining Steam

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

Dec 10, 2025, 1:31 PM EST - 6 weeks ago

Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv

BKNG FISV GD

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Dec 10, 2025, 12:42 PM EST - 6 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Dec 10, 2025, 12:20 PM EST - 6 weeks ago

Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial

Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

Dec 8, 2025, 2:46 PM EST - 6 weeks ago

Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Dec 7, 2025, 4:30 PM EST - 6 weeks ago

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Regeneron's experimental therapy combo effective in untreated cancer patients

Dec 6, 2025, 9:33 AM EST - 7 weeks ago

Regeneron's experimental therapy combo effective in untreated cancer patients

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 2:13 PM EST - 7 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 2, 2025, 4:53 PM EST - 7 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Dec 1, 2025, 7:00 AM EST - 7 weeks ago

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Nov 25, 2025, 1:00 AM EST - 2 months ago

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Nov 25, 2025, 1:00 AM EST - 2 months ago

Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

SNY

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

Nov 21, 2025, 11:05 AM EST - 2 months ago

This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead

LLY

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

Nov 20, 2025, 11:52 AM EST - 2 months ago

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Nov 19, 2025, 4:10 PM EST - 2 months ago

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Nov 19, 2025, 7:00 AM EST - 2 months ago

Libtayo® (cemiplimab) Approved in the European Union as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with High Risk of Recurrence after Surgery and Radiation

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 17, 2025, 1:07 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 17, 2025, 11:57 AM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Nov 13, 2025, 7:00 AM EST - 2 months ago

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Final Trade: LMAT, REGN, BA, TJX

Nov 12, 2025, 6:20 PM EST - 2 months ago

Final Trade: LMAT, REGN, BA, TJX

TJX BA LMAT

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript

Nov 10, 2025, 2:31 PM EST - 2 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

Nov 7, 2025, 8:00 AM EST - 2 months ago

Press Release: ACAAI: Sanofi and Regeneron's Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

SNY

Regeneron Announces Investor Conference Presentations

Nov 3, 2025, 4:05 PM EST - 2 months ago

Regeneron Announces Investor Conference Presentations

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Oct 31, 2025, 7:00 AM EDT - 3 months ago

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Oct 29, 2025, 1:00 PM EDT - 3 months ago

Regeneron Q3 Earnings Review: This Is The Start Of A Dupixent Driven Comeback

Market Starting To Embrace The 'New' Regeneron

Oct 29, 2025, 12:01 PM EDT - 3 months ago

Market Starting To Embrace The 'New' Regeneron

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 1:31 PM EDT - 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN) Q3 2025 Earnings Call Transcript

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Oct 28, 2025, 9:13 AM EDT - 3 months ago

Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness

Regeneron beats quarterly estimates on strong demand for Dupixent

Oct 28, 2025, 7:30 AM EDT - 3 months ago

Regeneron beats quarterly estimates on strong demand for Dupixent

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Oct 28, 2025, 6:30 AM EDT - 3 months ago

Regeneron Reports Third Quarter 2025 Financial and Operating Results

Has Regeneron Stock Quietly Become A Value Buy?

Oct 27, 2025, 8:35 AM EDT - 3 months ago

Has Regeneron Stock Quietly Become A Value Buy?

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

Oct 24, 2025, 4:30 AM EDT - 3 months ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IQV IVZ JNJ

7 Stocks Taking The Next Step To Be On Offense

Oct 23, 2025, 7:30 PM EDT - 3 months ago

7 Stocks Taking The Next Step To Be On Offense

ACI BIO CNX FCF FDX FIS IAC

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Oct 17, 2025, 7:30 AM EDT - 3 months ago

Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

Oct 15, 2025, 7:00 AM EDT - 3 months ago

Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Oct 12, 2025, 10:18 AM EDT - 3 months ago

DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?

Oct 10, 2025, 8:35 AM EDT - 3 months ago

What If You Were Missing The Value In Regeneron Pharmaceuticals Stock?

US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer

Oct 8, 2025, 4:31 PM EDT - 3 months ago

US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

Oct 8, 2025, 2:31 PM EDT - 3 months ago

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

11 Cheap Stocks for a Market That's Too Expensive

Oct 7, 2025, 11:49 AM EDT - 3 months ago

11 Cheap Stocks for a Market That's Too Expensive

DAL FDX UAL

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 3 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Regeneron: Growth Catalysts Incoming

Sep 30, 2025, 4:25 PM EDT - 4 months ago

Regeneron: Growth Catalysts Incoming

Information_Master
Information_Master Jan. 24 at 3:31 PM
PORTFOLIO UPDATE Natan YTD: +4.0% S&P500 YTD: +1.0% TOTAL RETURNS (Jan 2022) Natan's portfolio: +132.1% *Benchmark: +44.2% S&P500: +53.5% MY POSITIONS: 17.3% | Transmedics $TMDX 14.6% | Pinduoduo $PDD 9.4% | Alibaba $BABA 8.0% | Robinhood $HOOD 8.0% | Regeneron $REGN ...... 👉Click to view @Information_Master for timely updates amid the volatility..
0 · Reply
gargoyl
gargoyl Jan. 23 at 2:56 PM
$BLRX 🦍 👀 set up for beast mode … watch .. $VSTM $REGN $XBI
0 · Reply
gargoyl
gargoyl Jan. 23 at 6:41 AM
$BLRX the new trend is economic fundamentals after value as the bull trend broadens into full market, well, add growth to that and you have a perfect trifecta storm on a currently little 🧢 cap. Instinct says the appearance of manipulated weakness is a ruse for accumulation, but only until the second a milestone hits , most likely equivalent to current market cap, the veil be removed and MM can’t shade the demand in the dark pool and a tenuous spread book of wide Bid and Ask. Is today the day , it’s inevitable. Long the 🦋 🎯 $18 $XBI $REGN
0 · Reply
Iwannagofast1
Iwannagofast1 Jan. 22 at 3:08 PM
$REGN My 4 401K longs TSM INTC SNDK AMD . Do your thing. 13 shorts and have mass puts in liquid accts. Software getting killed still so that’s good news
0 · Reply
50bps
50bps Jan. 22 at 3:05 PM
$REGN 👀
0 · Reply
GT1313
GT1313 Jan. 22 at 2:58 PM
$REGN I need a 5% day
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 22 at 2:53 PM
$REGN they need to give a PR-update on the pending CRL?
0 · Reply
Dy2ski
Dy2ski Jan. 21 at 12:08 PM
$OCUL $MRK Interesting. Solid addition with the $REGN Eylea link beyond the possible acquisition link.
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 21 at 2:31 AM
$REGN Share Price: $733.95 Contract Selected: Feb 13, 2026 $740 Calls Buy Zone: $23.29 – $28.77 Target Zone: $43.52 – $53.20 Potential Upside: 76% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
tasha655
tasha655 Jan. 20 at 6:08 PM
$BMEA $REGN
0 · Reply
RandomInvestor777
RandomInvestor777 Jan. 20 at 2:24 PM
$CRVS Jefferies $REGN failed therapies $CRVS Dupixent ~$28BN in sales in 2030. but up to 50% of patients will fail systemic biologic therapy, and janus kinuse inhibitors (JAKi), simple math easily says 10-14 billion in just failure market
0 · Reply
trading_momentum_x
trading_momentum_x Jan. 17 at 4:15 AM
$NVO hasnt looked back since this bullish engulfing weekly, up over 20% since. Sitting on 2027 60C and shares. Healthcare rotation continues $LLY $MRK $REGN $BMY
0 · Reply
Arcides
Arcides Jan. 16 at 7:43 PM
$REGN longs this is not acting good. looking like a double top..
0 · Reply
johnrecoursa
johnrecoursa Jan. 16 at 7:34 PM
$REGN bought back my 60 shares. Have enough gunpowder to bring it back to 100 shares even.
0 · Reply
elitechrisvp
elitechrisvp Jan. 16 at 7:33 PM
$IBRX the next $REGN ✅️
0 · Reply
Iwannagofast1
Iwannagofast1 Jan. 16 at 7:01 PM
$REGN Don’t believe the 10% down move at all
0 · Reply
JetSetRepeat
JetSetRepeat Jan. 16 at 4:41 PM
$REGN how is this just dropping every day for over a week? Lol
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jan. 16 at 2:55 PM
$REGN 6 red days in a row on No news.
0 · Reply
gargoyl
gargoyl Jan. 15 at 2:24 PM
$BLRX 👀 - spoofing at 3.10 - past month channel consolidation between 2.80 and 3.10 - RSI primed break 60 - $XBI run 🏃‍♂️ - nearing next ER - MM playing the pull back game widening her book - my book All point to we break $3.00 today 💪 strong Target 🎯 $12 -$18 $REGN long the 🦋
0 · Reply
Indyshaw
Indyshaw Jan. 15 at 1:19 AM
$REGN all - check out a small company that Regeneron just recently signed a collaboration agreement with. $OPK
1 · Reply
Iwannagofast1
Iwannagofast1 Jan. 14 at 7:05 PM
$REGN This is doable and I’m happy w it . Let’s get back to $800 though
0 · Reply
nepepe
nepepe Jan. 14 at 1:53 PM
$ACRV $BMRN $LLY $REGN $VRTX
0 · Reply